

## **References for CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Blitz Campaign 2024 – Wave 1**

- 1.** Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA.
- 2.** Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
- 3.** Effect of CEQUA in Subjects with Dry Eye Disease, ClinicalTrials.gov identifier NCT04357795. Updated February 2024. Accessed August 29, 2023.  
<https://www.clinicaltrials.gov/study/NCT04357795>
- 4.** CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
- 5.** Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.

Current as of: August 21, 2024

© 2024 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-1563 08/2024